Advancing Precision-Targeted Treatment for Patients with Metastatic Non-Small Cell Lung Cancer

Monday, November 20, 2023

Location: Cypress 1

CE: 1.0 credit/hour

Speaker(s)

Tajuana Bradley, MSN, APRN-BC

Nurse Practitioner
Georgia Cancer Specialists, Gwinnett and Cumming Office. Affiliated with Northside Hospital Cancer Institute
Lawrenceville, Georgia, United States
Beth Sandy, MSN, CRNP

Nurse Practitioner Thoracic Oncology
Abramson Cancer Center, Hospital of the University of Pennsylvania
Marlton, New Jersey, United States

Disclosures:

Tajuana Bradley has served on speakers bureaus for ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Coherus, G1 Therapeutics, Puma Biotechnology, and Seagen.
Beth Sandy has served on the speakers bureaus for Amgen, AstraZeneca, Jazz Pharmaceuticals, Lilly, Merck, and Takeda, and as a consultant for AbbVie and Janssen.

Learning Objectives:

Evaluate pivotal clinical trials leading to recent FDA approvals of new molecular targeted treatment options for patients with metastatic non-small cell lung cancer (NSCLC), and related updates to clinical practice guidelines.
Differentiate recently validated predictive and prognostic biomarkers and their clinical relevance for treating patients with mNSCLC.
Integrate evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with mNSCLC.